CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
成人中枢神经系统白血病的诊断与管理
英文原题：Diagnosis and management of adult central nervous system leukemia.
查看英文原题
Diagnosis and management of adult central nervous system leukemia.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
中枢神经系统白血病（CNSL）是急性白血病治疗失败的重要原因之一。目前的预防方案已降低了复发率和改善了预后。然而，对于复发/难治性患者，准确的复发风险分层和治疗方案仍是尚未解决的临床挑战。近年来，随着造血干细胞移植（HSCT）和CAR-T 细胞细胞疗法在一些CNSL患者中显示出令人鼓舞的效果，CNSL治疗的进展已有报道。分子靶向药物以及基于抗体的药物的开发将为患者提供更多个性化治疗。本文总结了成人CNSL的危险因素、诊断、预防和治疗方面的最新研究进展。
展开英文摘要原文
Central nervous system leukemia (CNSL) is a prominent infiltration reason for therapy failing in acute leukemia. Recurrence rates and the prognosis have alleviated with current prophylactic regimens.
However, the accurate stratification of relapse risk and treatment regimens for relapsed or refractory patients remain clinical challenges yet to be solved. Recently, with hematopoietic stem cell transplantation (HSCT) and chimeric antigen receptor-T (CAR-T) cellular therapy showing encouraging effects in some CNSL patients, advances in treating CNSL have already been reported.
The development of molecular targeted agents as well as antibody-based drugs will provide patients with more personalized treatment. This article summarized recent research developments about risk factors, diagnosis, prevention, and treatment in adults with CNSL.
论文信息
- 作者
- Liu S、Wang Y
- 单位
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.China
- 文献类型
- 综述
- 期刊
- Blood science (Baltimore, Md.)2023 Jul
- 原文标识
- PubMed 37546706 · DOI 10.1097/BS9.0000000000000162